The BPC-157 vs TB-500 question comes up constantly in repair and recovery research because the two peptides appear in the same literature, the same product categories and the same blends — yet they share almost nothing structurally. BPC-157 is a 15-residue fragment of a gastric protein; TB-500 derives from thymosin β4, an actin-binding peptide. This guide compares origin, sequence, described mechanism, evidence quality and laboratory handling side by side, for research use only.
Key takeaways
- Different origins. BPC-157 is a synthetic partial sequence of body protection compound from gastric juice. TB-500 derives from thymosin β4, an intracellular actin-sequestering peptide abundant in platelets.
- Different sizes. BPC-157 is 15 residues, ≈1419.5 Da. The TB-500 fragment Ac-LKKTETQ is 7 residues, ≈889 Da; full-length thymosin β4 is 43 residues, ≈4963.5 Da.
- Different described mechanisms. BPC-157 is discussed around nitric oxide signalling, VEGFR2 upregulation and growth-factor receptor expression. Thymosin β4 fragments are discussed around G-actin sequestration and cell migration.
- Different evidence shapes. The BPC-157 corpus is large but concentrated in a few laboratories. The thymosin β4 corpus is older and more independently distributed, but concerns the full-length peptide rather than the fragment.
- Neither is an approved medicine. Both fall under WADA category S0 (non-approved substances), and both are supplied strictly for laboratory research.
- They are combined in the Wolverine, GLOW and KLOW research blends precisely because the described pathways are non-overlapping.
- Handling differs in one practical respect: BPC-157 and the TB-500 heptapeptide contain no oxidation-prone residues, whereas full-length thymosin β4 carries a methionine.
BPC-157 vs TB-500 at a glance
BPC-157 and TB-500 are unrelated molecules that occupy the same shelf in repair-and-recovery research. BPC-157 is a defined synthetic pentadecapeptide with a stable CAS identity; TB-500 is a market label most often corresponding to a seven-residue acetylated fragment of thymosin β4. The table below sets out the twelve comparisons that matter most in a laboratory context.
| # | Comparison | BPC-157 | TB-500 (thymosin β4 fragment) |
|---|---|---|---|
| 1 | Biological origin | Partial sequence of body protection compound, a protein from human gastric juice | Fragment of thymosin β4, an intracellular peptide abundant in platelets and most cell types |
| 2 | Chain length | 15 residues | 7 residues (fragment) or 43 residues (full-length Tβ4) |
| 3 | Sequence | GEPPPGKPADDAGLV | Ac-LKKTETQ (residues 17–23 of Tβ4) |
| 4 | Molecular weight | ≈ 1419.5 Da | ≈ 889 Da (fragment); ≈ 4963.5 Da (Tβ4) |
| 5 | CAS number | 137525-51-0 | 77591-33-4 for full-length Tβ4; no single widely used entry for the fragment |
| 6 | Terminal chemistry | Free N- and C-termini | Acetylated N-terminus |
| 7 | Described primary mechanism | Nitric oxide system interaction; VEGFR2 upregulation and internalisation | G-actin sequestration maintaining a releasable monomer pool |
| 8 | Reported cellular readouts | Fibroblast migration, FAK/paxillin phosphorylation, growth hormone receptor expression | Keratinocyte and endothelial migration, re-epithelialisation, cardiac cell migration |
| 9 | Shape of the evidence base | Large rodent corpus, concentrated in a small number of groups | Older, more distributed corpus — but almost entirely on full-length Tβ4 |
| 10 | Human data | Registered Phase I with unsubmitted results; three small pilot studies identified in a 2025 review | Full-length Tβ4 has reached prospective randomised wound research; the fragment has not |
| 11 | Oxidation-prone residues | None (no Cys, Met or Trp) | None in the fragment; methionine at position 6 in full-length Tβ4 |
| 12 | Regulatory position | Not approved anywhere; WADA S0 | Not approved anywhere; WADA S0 |
Different origins: gastric protein vs thymosin
The two peptides arrive from completely different biology. BPC-157 was derived by taking a partial sequence from a protein characterised in human gastric juice and synthesising it as a standalone 15-mer. Thymosin β4 is a naturally occurring intracellular peptide present in most mammalian cells, where it functions as the main G-actin sequestering agent; TB-500 takes its actin-binding motif and synthesises that alone.
There is a second asymmetry hidden in that sentence. BPC-157 does not exist as a discrete molecule in the body — it is a designed fragment, and the parent protein’s own biology is far less characterised than the fragment’s literature implies. Thymosin β4, by contrast, is a real endogenous species with a well-mapped intracellular role, and the fragment is the designed object. The naturally occurring member of each pair sits on opposite sides of the comparison.
That difference in provenance explains the difference in how each literature is framed. The BPC-157 papers are written in the language of cytoprotection and organ protection, following Robert’s gastric cytoprotection tradition. The thymosin β4 papers are written in the language of cytoskeletal cell biology.
Mechanism side by side
The mechanistic distinction is the practical heart of the comparison. Published BPC-157 work describes an effect on the local signalling environment — nitric oxide synthesis, angiogenic receptor availability, growth-factor receptor expression in resident fibroblasts. Published thymosin β4 work describes an effect on the cell’s internal machinery for moving, by buffering the pool of monomeric actin available for filament assembly.
In other words: one literature is mostly about the signals a cell receives; the other is mostly about the hardware a cell uses to respond. That is the honest version of the “complementary mechanisms” claim that circulates around blends, and it is why the two are rarely presented as substitutes for one another.
Evidence base compared
Counting papers is a poor way to compare these two. The more informative question is how the evidence is distributed: how many independent groups, how many model systems, and how much of it used the exact molecule being sold.
| Dimension | BPC-157 | TB-500 / thymosin β4 |
|---|---|---|
| Volume of preclinical work | Very large — hundreds of rodent reports | Substantial, spanning wound, cardiac, corneal and neural models |
| Independence of sources | Concentrated; one Zagreb-based group dominates | More distributed across independent laboratories |
| Molecule actually studied | The 15-mer itself, consistently | Overwhelmingly the 43-residue peptide, not the heptapeptide |
| Independent mechanistic replication | Some — Taiwanese groups reported the tendon fibroblast and VEGFR2 findings | Extensive for actin binding; the biochemistry is textbook |
| Human trials completed | None published; a Phase I result was never submitted | Prospective randomised wound research reported for full-length Tβ4 |
| Current expert framing | “Investigational” — 2025 narrative review | Well-characterised biology, no approved product |
The asymmetry is worth stating plainly. BPC-157 has more studies about the exact molecule you can buy. Thymosin β4 has better-founded, more independently replicated biology — but the material commonly sold as TB-500 is a fragment that most of that biology did not test. Neither position is stronger in every respect.
Why BPC-157 and TB-500 are studied together
The stated rationale for combining BPC-157 and TB-500 in research blends is that the described pathways do not overlap. One is reported to act on angiogenic and growth-factor signalling; the other on the actin machinery that lets cells migrate into a repairing region. Investigators exploring tissue-repair models sometimes want both variables present rather than isolating either.
That rationale is a hypothesis, not a finding. Published head-to-head or factorial studies comparing each peptide alone against the combination are scarce, so additive or synergistic effects should be treated as untested rather than demonstrated. In practice, blends are convenient for exploratory work and a poor choice for mechanistic work, where single-component vials give cleaner attribution.
Handling and solution preparation differences
Both peptides are water-soluble, both are supplied lyophilised, and both follow the same reconstitution procedure. The differences are in molarity arithmetic and in oxidation risk.
| Vial content | Diluent | Concentration | Per 0.1 mL | Notes |
|---|---|---|---|---|
| BPC-157 5 mg | 2 mL | 2.50 mg/mL | 250 mcg | ≈ 1.76 mM at MW 1419.5 |
| BPC-157 10 mg | 2 mL | 5.00 mg/mL | 500 mcg | ≈ 3.52 mM |
| TB-500 5 mg | 2 mL | 2.50 mg/mL | 250 mcg | ≈ 2.81 mM at MW 889 — higher molarity for the same mass |
| TB-500 10 mg | 2 mL | 5.00 mg/mL | 500 mcg | ≈ 5.62 mM |
| Worked example: blend stated as 5 mg + 5 mg | 2 mL | 2.50 mg/mL of each component | 250 mcg of each | Total peptide 5.00 mg/mL — read component masses from the batch label |
| Worked example: blend stated as 5 mg + 5 mg | 3 mL | 1.67 mg/mL of each component | 167 mcg of each | Total peptide 3.33 mg/mL |
Choosing between them for a research question
The choice follows from what the experiment is measuring, not from which compound has more search volume. A study of angiogenic signalling, vessel density or growth-factor receptor expression maps onto the BPC-157 literature. A study of cell motility, cytoskeletal dynamics or wound-edge migration maps onto the thymosin β4 literature.
- Define the readout first. Vessel counts, receptor expression and lesion scoring point one way; migration assays and actin imaging point the other.
- Check which molecule the source papers used. For thymosin β4 material especially, confirm whether the cited work used the 43-mer or the fragment.
- Prefer single-component vials for mechanistic work. A blend makes attribution impossible when a result appears.
- Match the molarity, not the mass. Comparing two peptides at the same mg/mL compares different numbers of molecules.
- Verify identity on the batch COA. Mass spectrometry settles what is actually in the vial before any of the above matters.
One further consideration applies to comparison experiments specifically. If a protocol runs BPC-157 and TB-500 arms side by side, the two arms should be matched on molar concentration and on diluent, and the vials should come from batches whose certificates were issued by the same analytical method. Otherwise a difference in outcome can reflect a difference in preparation rather than in the peptides.
Purity and identity checks are covered in the COA reading guide, and GenoPept publishes per-batch third-party certificates covering HPLC and MS at /coa-certificates/.
BPC-157 and TB-500 in the GenoPept store
Frequently asked questions
What is the main difference between BPC-157 and TB-500?
Origin and mechanism. BPC-157 is a 15-residue synthetic fragment of a gastric protein, described in published research as acting through nitric oxide signalling and VEGFR2 upregulation. TB-500 derives from thymosin β4 and is described as binding monomeric actin to support cytoskeletal remodelling and cell migration. They are structurally unrelated.
Are BPC-157 and TB-500 used together in research?
Yes — they appear together in the Wolverine, GLOW and KLOW research blends. The stated rationale is that their described pathways do not overlap. However, published factorial studies comparing each peptide alone against the combination are scarce, so any additive effect should be treated as an untested hypothesis rather than a demonstrated result.
Which has stronger published evidence?
It depends what you weight. BPC-157 has more studies on the exact molecule sold, but they are concentrated in a small number of laboratories. Thymosin β4 has better-replicated, more independently sourced biology, but most of it used the full 43-residue peptide rather than the heptapeptide fragment usually sold as TB-500.
Do BPC-157 and TB-500 have the same molecular weight?
No. BPC-157 is approximately 1419.5 Da. The TB-500 fragment Ac-LKKTETQ is approximately 889 Da, and full-length thymosin β4 is approximately 4963.5 Da. This matters when preparing solutions: identical mass concentrations correspond to very different molar concentrations.
What is the Wolverine blend?
The Wolverine blend is a single lyophilised vial containing both BPC-157 and TB-500, supplied for laboratory research. The mass of each component is stated on the batch label and certificate of analysis. Our blends guide compares Wolverine, GLOW and KLOW compositions.
Can BPC-157 and TB-500 be reconstituted in the same way?
Yes. Both dissolve readily in aqueous diluent, and the procedure is identical: equilibrate the vial, add diluent slowly down the wall, swirl rather than shake, inspect for clarity, then aliquot and label. The difference is arithmetic — the molar concentration produced by a given mg/mL differs between them.
Is either compound an approved medicine?
No. Neither BPC-157 nor thymosin β4 has been approved by a drug regulatory agency, and both fall under the World Anti-Doping Agency’s S0 category for substances with no current approval for human therapeutic use. Both are supplied strictly for laboratory research. This is general information, not legal advice.
Which should be selected for a cell migration assay?
The thymosin β4 literature maps more directly onto migration readouts, since actin sequestration is the described mechanism and Boyden chamber work is a recurring assay in that corpus. That said, BPC-157 has also been reported to increase fibroblast migration in tendon cell culture, so both appear in migration literature through different routes.
References
- Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design. 2011;17(16):1612–1632. PubMed
- Seiwerth S, Milavic M, Vukojevic J, et al. Stable gastric pentadecapeptide BPC 157 and wound healing. Frontiers in Pharmacology. 2021;12:627533. doi:10.3389/fphar.2021.627533
- Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JHS. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology. 2011;110(3):774–780. PubMed
- Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine. 2017;95(3):323–333. doi:10.1007/s00109-016-1488-y
- Cushman DM, et al. Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Current Reviews in Musculoskeletal Medicine. 2025;18(12):611–619. doi:10.1007/s12178-025-09990-7
- Malinda KM, et al. Thymosin beta4 accelerates wound healing. Journal of Investigative Dermatology. 1999;113(3):364–368. PubMed
- Goldstein AL, Hannappel E, Kleinman HK. Thymosin β4: actin-sequestering protein moonlights to repair injured tissues. Trends in Molecular Medicine. 2005. PubMed
- Esposito S, Deventer K, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Testing and Analysis. 2012. doi:10.1002/dta.1402
Research-grade BPC-157 and TB-500, batch-verified
GenoPept supplies BPC-157, TB-500 and the Wolverine blend as lyophilised vials with per-batch third-party certificates of analysis covering HPLC purity and mass-spectrometry identity, dispatched from the UK, strictly for laboratory research.